Company intelligence / Profile preview

Fennec Acquisition

Research Triangle Park, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Fennec achieved 40% year-over-year revenue growth in fiscal year 2024, with its flagship product PEDMARK demonstrating strong commercialization progress, particularly in the AYA oncology segment and international markets.[1] The company is positioned for significant growth in 2025 and beyond through market expansion and strategic partnerships.[1]

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Norgine Pharmaceuticals Ltd. (exclusive licensing agreement for European commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand, with €40 million upfront and up to €210 million in milestone payments)[6]

Beyond the preview

Go deeper on Fennec Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fennec Acquisition.

Explore the full profile